Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GM-CSF

0191680 - UMG-J 20033195 RIV GR eng J - Journal Article
Mikyšková, Romana - Indrová, Marie - Šímová, Jana - Jandlová, Táňa - Bieblová, Jana - Jinoch, P. - Bubeník, Jan - Vonka, V.
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GM-CSF.
International Journal of Oncology. Roč. 24, č. 1 (2004), s. 161-167. ISSN 1019-6439. E-ISSN 1791-2423
R&D Projects: GA MZd NC7148; GA MZd NC7552; GA ČR GA301/01/0985
Institutional research plan: CEZ:AV0Z5052915
Keywords : HPV16 * gene therapy * minimal residual tumour disease
Subject RIV: FD - Oncology ; Hematology
Impact factor: 3.056, year: 2004

Moderately immunogenic HPV16-associated tumours, MHC class I positive as well as negative, were used to examine the effects of local IL-2 and GM-CSF cytokine or gene therapy in the treatment of minimal residual tumour disease induced surgically or chemotherapeutically. Both types of neoplasms were found to be inhibited with adjuvant cytokine therapy. It is of interest to further investigate whether this is a general phenomenon in HPV16-associated tumour systems.
Permanent Link: http://hdl.handle.net/11104/0087418